SMARCA4 is altered in 8.59% of medulloblastoma patients [3].

SMARCA4 is an inclusion criterion in 9 clinical trials for medulloblastoma, of which 9 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

SMARCA4 is altered in 4.95% of malignant solid tumor patients [3].

SMARCA4 is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain SMARCA4 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 2 (3 open) [4].

SMARCA4 is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

SMARCA4 is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

SMARCA4 is an inclusion criterion in 3 clinical trials for rhabdoid tumor, of which 2 are open and 1 is closed. Of the trials that contain SMARCA4 status and rhabdoid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

SMARCA4 is altered in 9.86% of endometrial endometrioid adenocarcinoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].

SMARCA4 is altered in 7.81% of bladder carcinoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCA4 status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

SMARCA4 is altered in 6.25% of large cell/anaplastic medulloblastoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is altered in 6.01% of central nervous system embryonal neoplasm patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is altered in 5.08% of anaplastic astrocytoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

SMARCA4 is altered in 4.34% of non-hodgkin lymphoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

SMARCA4 is altered in 3.9% of lymphoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and lymphoma as inclusion criteria, 2 are phase 1 (1 open) [4].

SMARCA4 is altered in 2.99% of glioblastoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

SMARCA4 is altered in 2.41% of breast carcinoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCA4 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

SMARCA4 is altered in 0.83% of synovial sarcoma patients [3].

SMARCA4 is an inclusion criterion in 2 clinical trials for synovial sarcoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 2 are phase 1 (2 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for epithelioid sarcoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

SMARCA4 is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

SMARCA4 is altered in 13.66% of anaplastic oligodendroglioma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 8.99% of malignant ovarian clear cell tumor patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 8.59% of esophageal adenocarcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 7.71% of melanoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 6.85% of adenocarcinoma of the gastroesophageal junction patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 8.43% of non-small cell lung carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 5.0% of anaplastic pleomorphic xanthoastrocytoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 5.0% of esophageal squamous cell carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 5.57% of colorectal carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 5.93% of gastric adenocarcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 7.81% of sarcomatoid carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 4.35% of high-grade glioma, NOS patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 4.24% of ovarian endometrioid adenocarcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 4.35% of malignant ovarian endometrioid tumor patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 3.85% of diffuse glioma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 3.73% of malignant glioma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 3.46% of malignant central nervous system neoplasm patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 3.85% of head and neck carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 2.93% of pancreatic carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 3.89% of ovarian carcinoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 1.35% of ependymoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is altered in 2.27% of sarcoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 1.71% of soft tissue sarcoma patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA4 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCA4 is altered in 0.52% of acute myeloid leukemia patients [3].

SMARCA4 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for extrarenal rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and extrarenal rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for ovarian small cell carcinoma, hypercalcemic type, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ovarian small cell carcinoma, hypercalcemic type as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SMARCA4 is an inclusion criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [4].